United Therapeutics Corp. (UTHR)

118.65
0.20 0.17
NASDAQ : Health Technology
Prev Close 118.85
Open 119.30
Day Low/High 118.21 / 120.54
52 Wk Low/High 100.06 / 130.00
Volume 264.00K
Avg Volume 362.90K
Exchange NASDAQ
Shares Outstanding 43.72M
Market Cap 5.15B
EPS 13.50
P/E Ratio 8.79
Div & Yield N.A. (N.A)

Latest News

United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results

United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APPF, GOLD, GPRE, SPA, TOO, UTHR, WGO Downgrades: SU, TIGO Initiations: AQUA Read on to get TheStreet Quant Ratings' detailed report:

Arena Pharmaceuticals Announces Closing Of Global License Agreement With United Therapeutics For Ralinepag

Arena Pharmaceuticals Announces Closing Of Global License Agreement With United Therapeutics For Ralinepag

SAN DIEGO, Jan. 24, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of United Therapeutics Corporation - UTHR

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of United Therapeutics Corporation - UTHR

NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).

Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma

Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.

Arena Pharmaceuticals And United Therapeutics Announce Global License Agreement For Ralinepag

Arena Pharmaceuticals And United Therapeutics Announce Global License Agreement For Ralinepag

- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments

CollPlant Announces Closing Of Global Licensing And Commercialization Agreement With United Therapeutics For 3D Bioprinting Of Solid-Organ Scaffolds For Human Transplants

CollPlant Announces Closing Of Global Licensing And Commercialization Agreement With United Therapeutics For 3D Bioprinting Of Solid-Organ Scaffolds For Human Transplants

Collaboration Combines CollPlant's Proprietary rhCollagen-based BioInk Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities

Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors

Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.

United Therapeutics Corporation Reports Third Quarter 2018 Financial Results

United Therapeutics Corporation Reports Third Quarter 2018 Financial Results

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.

CollPlant And United Therapeutics Announce Global Licensing And Commercialization Agreement For 3D Bioprinting Of Solid-Organ Scaffolds For Human Transplants

CollPlant And United Therapeutics Announce Global Licensing And Commercialization Agreement For 3D Bioprinting Of Solid-Organ Scaffolds For Human Transplants

Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities

CollPlant And United Therapeutics Announce Global Licensing And Commercialization Agreement For 3D Bioprinting Of Solid-Organ Scaffolds For Human Transplants

CollPlant And United Therapeutics Announce Global Licensing And Commercialization Agreement For 3D Bioprinting Of Solid-Organ Scaffolds For Human Transplants

Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CNNE, GWRE, MDRX, VRA Downgrades: PDFS, RE, SB, SGRP, UTHR Initiations: CODX, NETS Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: LGL, UTHR Downgrades: CKX, ERF, GORO, GTS, XNET Initiations: TPNL Read on to get TheStreet Quant Ratings' detailed report:

5 Bearish Bets: Why Pepsi, Cray and 3 Other Stocks Look Good Short

5 Bearish Bets: Why Pepsi, Cray and 3 Other Stocks Look Good Short

Pepsi looks challenged and Cray's chart is 'cray cray.'

Pepsi Is Challenged, Cray’s Chart Is Cray Cray and 3 Other Stocks That Look Good Short

PEP, CULP, IT, CRAY and UTHR were all recently were downgraded by TheStreet's Quant Ratings service.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOI, ATSG, CKH, CRM, DDS, EQBK, FSTR, GNK, NEWM, OAS, RDC, RRC, TCMD, UHS, WTW Downgrades: AHGP, AMED, AXE, CTRE, CULP, DOC, EMKR, GLW, HABT, IT, KBR, RP, SGEN, SPOK, SWM, TACO, UGP, UTHR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against United Therapeutics Corporation - UTHR

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against United Therapeutics Corporation - UTHR

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of United Therapeutics Corporation (NASDAQ: UTHR) resulting from allegations that United...

Faruqi & Faruqi, LLP Is Investigating United Therapeutics Corporation (UTHR) On Behalf Of Its Shareholders

Faruqi & Faruqi, LLP Is Investigating United Therapeutics Corporation (UTHR) On Behalf Of Its Shareholders

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ:UTHR).

Short Interest Falls 20% For UTHR

Short Interest Falls 20% For UTHR

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,169,886 share decrease in total short interest for United Therapeutics Corp , to 4,652,309, a decrease of 20.09% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

United Therapeutics Gets a Quantitative Upgrade

United Therapeutics Gets a Quantitative Upgrade

Shares look to break out from long basing pattern.

TheStreet Quant Rating: B (Buy)